Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D2R3ZX
|
|||
| Drug Name |
Cendakimab
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Eosinophilic esophagitis [ICD-11: DA24.1; ICD-9: 530.13] | Phase 3 | [1] | |
| Company |
Bristol-Myers Squibb
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin-13 (IL13) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Jak-STAT signaling pathway | ||||
| Fc epsilon RI signaling pathway | ||||
| Measles | ||||
| Asthma | ||||
| Inflammatory bowel disease (IBD) | ||||
| NetPath Pathway | IL9 Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| IL2 Signaling Pathway | ||||
| Leptin Signaling Pathway | ||||
| TSLP Signaling Pathway | ||||
| Panther Pathway | Interleukin signaling pathway | |||
| Pathwhiz Pathway | Fc Epsilon Receptor I Signaling in Mast Cells | |||
| Pathway Interaction Database | Glucocorticoid receptor regulatory network | |||
| IL12 signaling mediated by STAT4 | ||||
| WikiPathways | SIDS Susceptibility Pathways | |||
| Cytokines and Inflammatory Response | ||||
| Allograft Rejection | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05214768) A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Induction and Maintenance Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Subjects With Eosinophilic Gastroenteritis. U.S.National Institutes of Health. | |||
| REF 2 | Biologics in eosinophilic gastrointestinal diseases. Ann Allergy Asthma Immunol. 2023 Jan;130(1):21-27. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.